...
首页> 外文期刊>International journal of oncology >Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma
【24h】

Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma

机译:过氧化物酶体增殖物激活受体γ在人胰腺癌中的表达及其预后意义

获取原文

摘要

Peroxisome proliferator-activated receptor?γ (PPARγ) is a ligand-activated nuclear receptor which has been implicated in carcinogenesis and angiogenesis in a wide range of cancers, including pancreatic carcinoma (PC). We aimed to characterize the prognosis and potential therapeutic implications of PPARγ in PC. Real-time RT-PCR and western blotting were used to quantify PPARγ expression in immortalized pancreatic epithelial cells, PC cell lines and freshly isolated matched tumor and non-tumor tissues. PPARγ protein expression was analyzed by immunohistochemistry (IHC) in archived tumor tissues from 101 PC patients. Furthermore, the effect of PPARγ on the cytotoxic action of gemcitabine (Gem) and 5-fluorouracil (5-FU) in PC cell lines was investigated in?vitro using RNA interference techniques. Both PPARγ protein and mRNA were expressed at markedly higher levels in all of the PC cell lines and freshly isolated PC tissues, compared to normal immortalized pancreatic epithelial cells and the matched adjacent non-tumor tissues. High levels of PPARγ expression correlated significantly with tumor-node-metastasis (TNM) staging (P<0.001) and poor overall survival (P<0.001), especially in patients with advanced disease who received postoperative chemotherapy. While silencing of PPARγ significantly inhibit the cytotoxic effects of both gemcitabine and 5-fluorouracil in PC cells in?vitro. This study suggests that high levels of PPARγ expression are associated with poor overall survival in PC. Additionally, PPARγ promotes chemoresistance in PC cells, indicating that PPARγ may represent a novel therapeutic target for PC.
机译:过氧化物酶体增殖物激活受体γ(PPARγ)是一种配体激活的核受体,与多种癌症(包括胰腺癌(PC))的癌变和血管生成有关。我们旨在表征PPARγ在PC中的预后和潜在的治疗意义。实时RT-PCR和蛋白质印迹法用于定量永生化胰腺上皮细胞,PC细胞系以及新鲜分离的匹配肿瘤和非肿瘤组织中的PPARγ表达。通过免疫组织化学(IHC)分析了101名PC患者归档肿瘤组织中的PPARγ蛋白表达。此外,使用RNA干扰技术体外研究了PPARγ对吉西他滨(Gem)和5-氟尿嘧啶(5-FU)在PC细胞系中的细胞毒性作用的影响。与正常的永生化胰腺上皮细胞和匹配的相邻非肿瘤组织相比,在所有PC细胞系和新鲜分离的PC组织中PPARγ蛋白和mRNA的表达均显着较高。 PPARγ的高表达与肿瘤淋巴结转移(TNM)分期(P <0.001)和较差的总体生存率(P <0.001)显着相关,特别是在接受过化疗的晚期疾病患者中。 PPARγ沉默可显着抑制吉西他滨和5-氟尿嘧啶对PC细胞的体外细胞毒性作用。这项研究表明,高水平的PPARγ表达与PC整体生存期差有关。此外,PPARγ促进PC细胞的化学耐药性,表明PPARγ可能代表PC的新型治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号